Durata Therapeutics Revenue, Profits - DRTX Annual Income Statement

Add to My Stocks
$24.16 $0.41 (1.73%) DRTX stock closing price Nov 17, 2014 (Closing)

Financial analysis of Durata Therapeutics involves more than just checking the Durata Therapeutics stock price, by looking at the financial statements of the company in detail. The income statement gives the investor an understanding of the topline or revenue and bottomline or profit numbers of the company and helps investors evaluate if a company has been growing or not. The income statement is always for an accounting period, typically for a year or quarter, and affects the stock. In this case, the DRTX stock is bound to reflect the impact of the YOY decline of 0. The operating expenses as shown in the Durata Therapeutics profit and loss statement for 2013 total to $56.96M. This line item shows that the operating expenses has decreased compared with last year. Also check: Durata Therapeutics assets and Durata Therapeutics free cash flow.

View revenue and profit details for latest and last 10 financial years.
show more
Fiscal year is Jan - Dec2013201220112010
Durata Therapeutics Revenues or Net Sales
----
Cost Of Goods Sold (COGS)----
Durata Therapeutics Gross Profit
----
Research & Development Expense37.31M51.69M30.13M4.81M
Selling General & Admin Expense19.65M10.88M5.42M9.07M
Income Before Depreciation Depletion Amortization-56.97M-62.57M-35.55M-13.89M
Depreciation Depletion Amortization----
Non Operating Income-1.66M---
Interest Expense2.22M---
Durata Therapeutics Pretax Income
-60.86M62.53M35.54M13.89M
Provision for Income Taxes1.27M--2.51M-2.87M
MinorityInterest----
Investment Gains Losses----
Other Income----
Income Before Extraordinaries & Disc Operations-62.14M62.53M38.05M16.77M
Extraordinary Items & Discontinued Operations----
Durata Therapeutics Profit/ Loss (Net Income)
-62.14M-62.53M-33.03M-11.01M
Average Shares used to compute Diluted EPS24.23M8.36M--
Average Shares used to compute Basic EPS24.23M8.36M--
Income Before Nonrecurring Items-60.01M-61.44M--
Income from Nonrecurring Items-2.13M-1.1M--
Durata Therapeutics Earnings Per Share Basic Net
-2.57-7.48--
Durata Therapeutics Earnings Per Share Diluted Net
-2.57-7.48--
EPS Diluted Before Nonrecurring Items-2.48-7.35--
Preferred Dividends Acc Pd----
Dividends Common----
Dividend Per Share Common0.000.000.000.00
All figures in USD. M: Millions of USD, B: Billions of USD.

The key things to look for in an income statement while doing Durata Therapeutics stock analysis are:

  • Revenue: This is the inflow that is generated from the sale of goods or services and is $- for this year of 2013. Our Durata Therapeutics revenue chart gives a clear visual representation of how the topline or sales growth has been. Investors often invest only in those companies where the revenue is growing at a steady rate.
  • Bottom line: The word bottom line comes because it is usually the last line of the income statement and refers to the actual profits after deducting all expenses from the revenues. DRTX stock had a healthy bottom line growth.

The income statement is also called the profit and loss statement. Apart from the DRTX income statement, one can check the Durata Therapeutics historical stock prices to check how the price has moved with time.